Breaking Canadian GLP-1 news
GLP-1 News — Page 6
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Health Canada Confirms G7-First Status After Apotex Generic Nod
Health Canada confirms G7-first generic semaglutide status after authorizing Apotex's version, with seven additional submissions still under active review.
Generic Semaglutide Pipeline: 7 Submissions Still Under Review
Health Canada confirms seven generic semaglutide submissions remain under review after the second approval on May 1, 2026, with more decisions expected.
Ozempic Topped Canadian Drug Sales at $2.9B in 2025: IQVIA
Ozempic was Canada's best-selling drug in 2025 with $2.9B in sales, more than triple the next-ranked medication, IQVIA data shows as generics arrive.
Apotex Won't Manufacture Generic Semaglutide in Canada
Apotex president Martin Arès confirms generic semaglutide pens won't be made at Canadian facilities, citing specialized manufacturing requirements.
Apotex Wins Health Canada Nod for 2nd Generic Semaglutide
Health Canada authorized Apotex's generic semaglutide injection on May 1, 2026, the second generic of Ozempic approved in the G7, with 7 more submissions in review.
Health Canada Reviewing 8 More Generic Semaglutide Submissions
Health Canada says decisions on 8 remaining generic semaglutide submissions are expected in coming weeks and months after Dr. Reddy's first approval.
Provincial Coverage of Generic Semaglutide Uncertain After G7-First Approval
Canada became the first G7 country to approve generic semaglutide, but provincial drug plan coverage remains uncertain and varies by province.
Wegovy Pricing Snapshot: Retail $400–$570, Generic Seen Summer 2026
Teletest pegs Wegovy at $400–$570/month in Canada with a generic projected for summer 2026 at $40–$160, while employer coverage data shows narrow access.
Generic Semaglutide Starts at 75% of List Price Under pCPA Rules
Canada's generic pricing framework starts Dr. Reddy's semaglutide at 75% of Ozempic's $228 four-week list price, dropping to 35% with three approved makers.
Generic Semaglutide Filing Dates: How Long Apps Have Waited
Health Canada's generic submissions tracker and Globe and Mail reporting reveal generic semaglutide applications dating back to February 2024 still under review.
Felix Publishes Generic Semaglutide Price Tiers: $112-$240 Per Pen
Telehealth provider Felix outlines a tiered generic semaglutide pricing forecast ranging from $240 down to $112 per pen as more competitors enter Canada's market.
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spending is unlikely to decline even as a semaglutide generic is expected mid-2026.
CDA Draft: Cover Mounjaro With 25-49% Discount at Higher Doses
Canada's Drug Agency draft report recommends public plans cover Mounjaro for Type 2 diabetes if Eli Lilly grants 25-49% discounts at higher dosages.
Ozempic Tops Canadian Public Drug Spending at $807M: CIHI
Ozempic accounted for $807 million of the $20.1 billion spent on public drug plans across Canada, according to CIHI data released in March 2026.
Health Canada Pausing Generic Semaglutide Reviews, Spokesperson Confirms
Health Canada confirms it pauses generic semaglutide reviews when data is missing, with the clock stopping while manufacturers respond to information requests.
Pharmacy Expert Projects $100/Month Generic Semaglutide in Canada
University of Toronto pharmacy expert Mina Tadrous estimates Canadian generic semaglutide could land near $100 monthly once enough approved versions reach pharmacies.
Endoscopic Procedure Shows Promise for Patients Stopping Tirzepatide
Interim trial data show duodenal mucosal resurfacing helped tirzepatide patients retain over 80% of weight loss after stopping the drug, Reuters reports.
Sandoz CEO Calls Canada World's Second-Largest GLP-1 Market
Sandoz CEO Richard Saynor describes Canada as the world's second-largest GLP-1 market, raising cross-border supply concerns as generics near approval.
TrumpRx GLP-1 Deal Unlikely to Lower Canadian Prices, Experts Say
US TrumpRx program starts GLP-1 prices at US$350, dropping to US$245 over two years, but Canadian prices are already lower and generics loom.
Quebec Public Insurance Declines to Cover Wegovy, Citing Cost
Quebec's health research institute says Wegovy's cost is too high and benefits uncertain, keeping the Novo Nordisk semaglutide pen off the province's public formulary.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada